PMID: 11315356Apr 24, 2001Paper

Monoclonal antibodies and other biologic therapies

Lupus
V Strand

Abstract

The treatment of systemic lupus erythematosus (SLE) presents a significant therapeutic challenge: multi-organ involvement and a variable disease course characterized by clinical exacerbations and remissions make it difficult to predict outcome. Few products have been specifically developed in this clinical indication and most accepted therapies have not been tested in randomized controlled trials in SLE. A variety of biologic agents under investigation as potential treatments for SLE are designed to interfere with specific immunologic responses, hopefully avoiding generalized immunosuppression. These include therapies to downregulate IL-10 and/or upregulate TGFb production. Agents which interfere with T cell activation and T cell-B cell collaboration, such as CTLA4-Ig and anti-CD40 ligand monoclonal antibodies, may result in long term therapeutic benefit; alone or in combination, even following brief treatment courses. Products designed to decrease production of anti-dsDNA antibodies or inhibit complement activation may prevent immune complex deposition and amerliorate organ-specific manifestations such as renal disease. More aggressive interventions include gene therapy and stem cell transplantation. As these agents enter clin...Continue Reading

References

Aug 26, 1994·Science·B K FinckD Wofsy
Aug 1, 1995·Nature Medicine·L A Matis, S A Rollins
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y WangL A Matis
Jan 1, 1996·Annual Review of Immunology·T M FoyR J Noelle
Feb 1, 1996·Arthritis and Rheumatism·A CardenalD J McCarty
Sep 1, 1996·Immunology Today·I S Grewal, R A Flavell
Oct 31, 1996·The New England Journal of Medicine·H Reiser, M J Stadecker
Dec 1, 1996·International Archives of Allergy and Immunology·J Alcocer-VarelaD Alarcón-Segovia
Oct 23, 1997·The Journal of Clinical Investigation·H ZhangY Chen
Jun 26, 1998·Annals of the Rheumatic Diseases·C H EvansP D Robbins
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·G M IversonD M Marquis
Jan 27, 1999·Arthritis and Rheumatism·C H EvansP D Robbins
May 4, 1999·The Journal of Clinical Investigation·J R AbramsS Kang
Jun 3, 1999·The New England Journal of Medicine·E C GuinanJ G Gribben

❮ Previous
Next ❯

Citations

Oct 9, 2003·Current Rheumatology Reports·Lisa G Criscione, David S Pisetsky
May 23, 2002·Journal of the American College of Surgeons·Jean C Emond
Nov 25, 2003·Seminars in Nephrology·Wanfang Su, Michael P Madaio
Oct 18, 2001·Current Opinion in Rheumatology·T LeeC Sandborg
Aug 23, 2002·Current Opinion in Rheumatology·Hector Molina
Aug 23, 2002·Current Opinion in Rheumatology·Bryan D Gescuk, John C Davis
Jan 8, 2003·Drugs·Dudy G Kuiper-Geertsma, Ronald H W M Derksen
May 14, 2011·Autoimmunity Reviews·Guillermo J Pons-EstelRicard Cervera
Nov 7, 2002·Critical Care Clinics·Ghulam SaydainSuhail Raoof
Apr 6, 2005·Lupus·S Vasoo, G R V Hughes
Mar 1, 2005·Lupus·H Tahir, D A Isenberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.